This suggests that the mutant allele was either lost from the metastatic tumor or the metastatic deposit arose from a KRAS wildtype clone in the primary tumor and highlights the importance of assessing clinically actionable markers in the metastatic rather than primary tumor sample. Here, KRAS is linked to metastatic neoplasm.